Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
The present invention provides a medicine comprising a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.
1. A pharmaceutical composition comprising
a Toll-like receptor agonist,
lymphocyte activation gene 3 (LAG-3) protein or a fusion protein of an extracellular domain of LAG-3 protein and IgG, and
an HSP70-derived peptide consisting of SEQ ID NO: 7 and a GPC3-derived peptide consisting of SEQ ID NO: 16.
2. The pharmaceutical composition according to claim 1 , wherein the Toll-like receptor agonist is a Toll-like receptor 3 agonist or a Toll-like receptor 9 agonist.
3. The pharmaceutical composition according to claim 1 , wherein the Toll-like receptor agonist is Poly I:C or a salt thereof.
4. The pharmaceutical composition according to claim 3 , wherein the Poly I:C is Poly ICLC.
5. A pharmaceutical composition comprising
a preparation comprising a Toll-like receptor agonist,
a preparation comprising lymphocyte activation gene 3 (LAG-3A protein or a fusion protein of the extracellular domain of LAG-3 protein and IgG, and
a preparation comprising an HSP70-derived peptide consisting of SEQ ID NO: 7 and a GPC3-derived peptide consisting of SEQ ID NO: 16
wherein the preparations are formulated for combined administration.
6. The pharmaceutical composition according to claim 5 , wherein the Toll-like receptor agonist is a Toll-like receptor 3 agonist or a Toll-like receptor 9 agonist.
7. The pharmaceutical composition according to claim 5 , wherein the Toll-like receptor agonist is Poly I:C or a salt thereof.
8. The pharmaceutical composition according to claim 7 , wherein the Poly I:C is Poly ICLC.